Business Context and Reporting Period
This Form 8-K Current Report was filed by Oramed Pharmaceuticals Inc. on November 5, 2012, covering events that occurred on October 30, 2012, and August 8, 2012. The company is a Delaware corporation headquartered in Jerusalem, Israel.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses on corporate actions and equity transactions rather than operational financial performance.
Material Changes and Corporate Actions
- Securities Purchase Agreement: On October 30, 2012, the Company entered into an agreement with D.N.A Biomedical Solutions Ltd. ("D.N.A").
- Equity Issuance: The Company issued 2,390,057 shares of its common stock to D.N.A for no consideration.
- Warrant Receipt: In exchange, D.N.A issued the Company a fully vested warrant exercisable for up to 21,637,611 Ordinary Shares of D.N.A. The warrant expires on October 29, 2022.
- Valuation Basis: The share counts were determined based on the average closing market prices of the respective shares over the 30-day period prior to closing.
- Executive Compensation Adjustment: On August 8, 2012, the Board extended the term of a warrant held by Dr. Miriam Kidrorn (CTO and Director) by 24 months. The warrant is exercisable until August 6, 2014, for 3,361,630 shares at an exercise price of $0.001 per share.
- Stock Plan Restructuring: The Board cancelled the 2006 Stock Option Plan and reallocated its reserved pool of 3,000,000 shares to the 2008 Stock Incentive Plan. No options were outstanding under the 2006 Plan at the time of cancellation.
Guidance, Outlook, and Risks
The Company plans to exercise the warrant received from D.N.A upon receipt of approval from the Tel Aviv Stock Exchange Board of Directors to list the underlying Ordinary Shares. D.N.A has already filed an application for this approval. The filing does not contain specific forward-looking financial guidance, risk factors, or discussion of contingencies beyond the pending regulatory approval for the warrant exercise.
Investor Verification Checklist
- Verify the status of D.N.A's application for listing approval with the Tel Aviv Stock Exchange.
- Confirm the dilution impact of the 2,390,057 shares issued to D.N.A on existing shareholders.
- Monitor the exercise timeline for the D.N.A warrant (expires October 29, 2022) and the Dr. Kidrorn warrant (expires August 6, 2014).
- Review the 2008 Stock Incentive Plan to understand the availability of the reallocated 3,000,000 shares.